• Home
  • Store
    • Total Access Subscriptions
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Toolkit
  • FAQs
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Access Purchased Content
Home » Authors » Daniel Carlat, MD

Articles by Daniel Carlat, MD

Fact Sheet

Tetrabenazine (Xenazine) Fact Sheet for General Psychiatry

January 1, 2026
Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Tetrabenazine was the original vesicular monoamine transporter inhibitor brought to market and approved for the treatment of Huntington’s disease. 




Read More
Fact Sheet

Metformin (Glucophage, Glumetza, Riomet) Fact Sheet for Genearl Psychiatry

January 1, 2026
Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Metformin is a medication for type 2 diabetes that increases insulin sensitivity and decreases appetite. 




Read More
Fact Sheet

Deutetrabenazine (Austedo) Fact Sheet for Genearl Psychiatry

January 1, 2026
Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Deutetrabenazine was the second of the vesicular monoamine transporter inhibitors to be approved for the treatment of tardive dyskinesia (TD) in 2017.




Read More
Fact Sheet

Benztropine (Cogentin) Fact Sheet for General Psychaitry

January 1, 2026
Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Benztropine is an anticholinergic medication that is the go-to agent for treating and preventing antipsychotic-induced extrapyramidal symptoms (EPS).




Read More
Fact Sheet

Amantadine (Gocovri, Symmetrel) Fact Sheet for General Psychiatry

January 1, 2026
Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Amantadine is a dopaminergic medication used primarily in Parkinson’s disease, but it is also helpful in drug-induced parkinsonism and has fewer anticholinergic side effects (eg, cognitive impairment, dry mouth, constipation) than other meds used to combat extrapyramidal symptoms (EPS), like benztropine.




Read More
Fact Sheet

Vardenafil (Levitra) Fact Sheet

January 1, 2026
Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Vardenafil has similar efficacy to other phosphodiesterase type 5 (PDE-5) inhibitors.




Read More
Fact Sheet

Testosterone (various) Fact Sheet

January 1, 2026
Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Successful marketing has convinced the public that “low T” is a public health scourge, leading to overprescribing of testosterone for patients who don’t need it. Prescribe it only for men with demonstrably low testosterone levels and accompanying symptoms.




Read More
Fact Sheet

Tadalafil (Cialis) Fact Sheet

January 1, 2026
Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

We have fewer data for tadalafil in the psychiatric setting; however, compared to other agents in the class, its long duration of action may improve spontaneity, and the lack of interaction with meals may offer advantages. 




Read More
Fact Sheet

Sildenafil (Viagra) Fact Sheet

January 1, 2026
Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Flibanserin, marketed as the “pink Viagra,” is mildly effective for enhancing sexual desire, but with potentially significant side effects and precautions regarding alcohol use around the time of administration.




Read More
Fact Sheet

Flibanserin (Addyi) Fact Sheet

January 1, 2026
Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Flibanserin, marketed as the “pink Viagra,” is mildly effective for enhancing sexual desire, but with potentially significant side effects and precautions regarding alcohol use around the time of administration.




Read More
Previous 1 2 3 4 5 6 7 8 9 … 55 56 Next
Try The New AskCarlat AI

Ask any clinical question—our AI responds using only the peer-reviewed, editorially vetted content from Carlat Publishing.

Available In The Carlat Toolkit
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • MFB8e_SpiralCover.png

    Medication Fact Book for Psychiatric Practice, Eighth Edition (2026)

    Updated 2026 prescriber's guide.
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2772531237.jpg
    General Psychiatry

    Gender Affirming Care in Exile: The Lawsuits

    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2026 Carlat Publishing, LLC and Affiliates, All Rights Reserved.